Literature DB >> 8639068

The occurrence of depression in Parkinson's disease. A community-based study.

E Tandberg1, J P Larsen, D Aarsland, J L Cummings.   

Abstract

OBJECTIVE: To investigate the frequency of major depression (MD) and the severity of depressive symptoms among patients with Parkinson's disease (PD).
DESIGN: The PD population was derived from a community-based prevalence study. Total case ascertainment and a high diagnostic accuracy of PD were attempted through a detailed community study and the use of a new clinical diagnostic classification. Major depression was diagnosed according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. The severity of depression in the prevalence population was scored with the Montgomery and Asberg Depression Rating Scale. The occurrence of depressive symptoms among patients with PD was compared with the occurrence among age-matched groups of patients with diabetes mellitus and of healthy elderly. In addition, the patients with PD and the control groups completed the Beck Depression Inventory.
SETTING: Depression among patients with PD derived from a prevalence study in the county of Rogaland, Norway. PATIENTS: Two hundred forty-five patients with PD. Two age-matched control groups (each including 100 patients); one group included patients with diabetes mellitus and the other, healthy elderly.
RESULTS: Of the 245 patients with PD, 7.7% met the criteria for MD. Based on their Montgomery and Asberg Depression Rating score, 5.1% of the patients were moderately to severely depressed whereas another 45.5% had mild depressive symptoms. Among the patients who scored 20 or more on the Mini-Mental State Examination, 3.6% had MD compared with 25.6% of the patients with a score below 20. The frequency of patients with a Beck Depression Inventory score of 18 or more was higher in the PD group (24.1%) than among patients with diabetes mellitus (11%) and the healthy elderly controls (4%).
CONCLUSION: This study suggests that the prevalence of MD in PD is lower than previously assumed, but a substantial proportion of patients with PD have less severe depressive symptoms.

Entities:  

Mesh:

Year:  1996        PMID: 8639068     DOI: 10.1001/archneur.1996.00550020087019

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  89 in total

Review 1.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  D Aarsland; K Karlsen
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

2.  Health related quality of life in Parkinson's disease: a prospective longitudinal study.

Authors:  K H Karlsen; E Tandberg; D Arsland; J P Larsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-11       Impact factor: 10.154

Review 3.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

4.  Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson's disease.

Authors:  Roseanne D Dobkin; Jade Tiu Rubino; Lesley A Allen; Jill Friedman; Michael A Gara; Margery H Mark; Matthew Menza
Journal:  J Consult Clin Psychol       Date:  2012-03-12

Review 5.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

Review 6.  A tune in "a minor" can "b major": a review of epidemiology, illness course, and public health implications of subthreshold depression in older adults.

Authors:  Thomas W Meeks; Ipsit V Vahia; Helen Lavretsky; Ganesh Kulkarni; Dilip V Jeste
Journal:  J Affect Disord       Date:  2011-03       Impact factor: 4.839

7.  An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson's disease.

Authors:  Charles M Epstein; Marian L Evatt; Agnes Funk; Lhys Girard-Siqueira; Nichole Lupei; Larisa Slaughter; Saima Athar; Joanne Green; William McDonald; Mahlon R DeLong
Journal:  Clin Neurophysiol       Date:  2007-08-21       Impact factor: 3.708

Review 8.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

Review 9.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

Review 10.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.